What Zoladex Does
Zoladex (goserelin acetate) is a GnRH agonist that suppresses sex hormone production by initially stimulating then chronically suppressing pituitary gonadotropin secretion, leading to medical castration in men (testosterone suppression) and postmenopausal-level estrogen suppression in women within 2-4 weeks. 1
Mechanism of Action
Zoladex works through a biphasic mechanism:
Initial Phase (First 1-2 weeks): As a GnRH agonist, Zoladex initially increases LH and FSH secretion from the pituitary, causing a temporary rise in testosterone (men) or estradiol (women). This "tumor flare" phenomenon can temporarily worsen symptoms in the first few weeks. 1
Chronic Phase (After 2-4 weeks): Continuous exposure to Zoladex causes down-regulation of pituitary GnRH receptors, leading to sustained suppression of gonadotropin secretion. This results in:
- In men: Testosterone falls to castrate levels (≤50 ng/dL) within 2-4 weeks, maintained throughout therapy 1, 2
- In women: Estradiol drops to postmenopausal levels within 3 weeks 1
Clinical Applications
Prostate Cancer
Zoladex achieves medical castration equivalent to surgical orchiectomy for palliative treatment of advanced prostate cancer. The 3.6 mg depot maintains testosterone suppression for 28 days, while the 10.8 mg formulation works for 12 weeks. 3, 1, 4, 2
Breast Cancer
In premenopausal women with hormone receptor-positive breast cancer, Zoladex provides ovarian suppression as part of adjuvant endocrine therapy. When combined with tamoxifen or aromatase inhibitors, it improves disease-free survival. 5, 6
Other Gynecologic Conditions
- Endometriosis: Suppresses estrogen to reduce endometrial implants
- Uterine fibroids: Reduces fibroid volume by 20-30% within 12 weeks, often used preoperatively 7, 8
Prevention of Treatment-Induced Bone Loss
Zoladex and other GnRH agonists cause accelerated bone loss (2-10 fold higher than normal aging), increasing fracture risk. Bisphosphonates should be considered for patients with T-score ≤-1.5, age >65, or other fracture risk factors. 9
Important Clinical Considerations
Tumor Flare Warning: The initial hormone surge can cause temporary symptom worsening, including increased bone pain, urinary obstruction in prostate cancer, or spinal cord compression. Monitor closely during the first 2-4 weeks. 1
Contraception Required: Despite amenorrhea, pregnancy is possible during treatment. Women of childbearing potential must use effective non-hormonal contraception during therapy and for 12 weeks after discontinuation. 1
Cardiovascular and Metabolic Effects: GnRH agonists increase risk of diabetes, myocardial infarction, and stroke. Monitor glucose/HbA1c periodically and manage cardiovascular risk factors. 1
Hormone Recovery: After stopping Zoladex, LH, FSH, and sex hormone levels typically return to pretreatment values within 12 weeks. 1